Sareum Holdings has received approval for its application submitted for initiation of a Phase I clinical trial of SDC-1801 in Australia.
Cambridge, UK, 28 July 2022 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, today announces that it has submitted an application for a Clinical Trial Authorisation (“CTA”) to the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) for the development of SDC-1801 as a potential new therapeutic for a range of autoimmune diseases with a focus on psoriasis.
Cambridge, UK, 26 April 2022 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that its CEO, Dr Tim Mitchell, will give a Company Showcase presentation at the BioTrinity 2022 conference, being held in London on 26 and 27 April.
Cambridge, UK, 13 April 2022 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, Inc (“Sierra”), the licence holder for SRA737 (a novel Chk1 inhibitor), has agreed to be acquired by GlaxoSmithKline plc (“GSK”) for US$1.9 billion in cash. The transaction is expected to close in the third quarter of 2022 or before. GSK has noted that the key driver of the acquisition was momelotinib, a drug Sierra is developing for the treatment of myelofibrosis, which reported positive topline results in a Phase III study in January 2022..
Cambridge, UK, 11 April 2022 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that, further to its announcement on 15 December 2021, the European Patent Office has now issued a formal notification of grant for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 inhibitor programme. The patent will come into effect on 4 May 2022.
Cambridge, UK, 17 December 2021 – Sareum Holdings nplc (AIM: SAR), the specialist small molecule drug development company, nannounces that it has raised approximately £1.63 million, before nexpenses, through a subscription by new and existing high net worth nindividuals (the “Subscribers”) for 32,636,311 new ordinary shares of n0.025p each in the capital of the Company (“Ordinary Shares”) (the n“Subscription Shares”) at a price of 5.0p per share (the “Subscription nPrice”) (the “Subscription”).
Shares of Sareum Holdings plc (SAR.L) were gaining around 12 percent in London trading after the specialist drug development company announced Thursday that the United States Patent and Trademark Office has granted patent for its proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme or SDC-1802 Programme
Cambridge, UK, 3 December 2020 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that, further to the Company’s announcement on 27 October 2020, the Grant Offer Letter from UK Research & Innovation (“UKRI”) has been received and approved. This confirms Sareum’s successful application for approximately £174,000 in grant funding (the “Grant”) to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in severe-phase Covid-19.
Cambridge, UK, 8 October 2020 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the “SDC-1802 Programme”). This programme is in preclinical development and targets cancer and cancer immunotherapy.